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Abstract
Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of acquired thrombo-
cytopenia in children. The objective of this study was to evaluate the presenting features, variation in 
the clinical courses, initial response rate to therapy, and long-term outcome in patients with ITP . 
Materials and Methods: Three hundred and fifty out of 491 newly diagnosed patients with ITP 
between the initial diagnosis ages of 6 months to 16 years were included in this retrospective, descrip-
tive study. Patients with acute vs chronic ITP , acute vs recurrent ITP and chronic vs recurrent ITP were 
compared in terms of age at diagnosis, gender, initial platelet count, response rate to initial therapy, 
long-term outcome, and total duration of follow-up. 
Results: The clinical courses of the patients were determined as acute, chronic and recurrent in 63.8%, 
29.1%, and 7.1%, respectively. Platelet count >20x109/L and initial diagnosis age >10 years were 
found to increase the probability of chronic outcome by at least two-fold. 
Conclusion: It is concluded that ITP in childhood is a common disease with low morbidity and mortal-
ity. In addition to the acute and chronic form, a rare recurrent form, which accounts for about 4-7% 
of all ITP patients, should be considered. (Turk J Hematol 2010; 27: 147-55)
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Özet
Amaç: İmmun trombositopenik purpura (ITP) çocukluk çağında en sık görülen edinsel trombosito-
peni nedenlerindendir. Bu çalışmada, ITP’li çocuklarda başvuru bulguları, klinik seyirlerindeki 
farklılıklar, tedaviye ilk yanıt ve uzun dönem prognozlarının değerlendirilmesi amaçlandı.
Yöntem ve Gereçler: Bu retrospektif, tanımlayıcı araştırmaya tanı yaşı 6 ay-16 yıl olan ITP’li 491 has-
tadan 350’si dahil edildi. Akut, kronik ve rekürren ITP’li olgular tanı yaşı, cinsiyet, başvurudaki trom-
bosit sayısı, ilk tedavi yanıtı, prognoz ve izlem süreleri yönünden ikili gruplar halinde karşılaştırıldı. 
Bulgular: Hastaların %63.8’i akut, %29.1’i kronik ve %7.1’i rekürren ITP olarak tanımlandı. Trombosit Introduction
Immune thrombocytopenic purpura (ITP) is a 
common acquired bleeding disorder characterized 
by increased destruction of antibody-sensitized plate-
lets with normal to increased megakaryocytes in the 
bone marrow, presence of thrombocytopenia with 
otherwise normal red cells and leukocytes, absence 
of splenomegaly, and absence of other causes of 
thrombocytopenia [1,2]. Variability in the natural his-
tory and response to therapy suggest that ITP com-
prises a heterogeneous pathophysiology [3]. ITP 
affects infants, children, and adults; in the majority 
of the children, it is an acute, self-limiting disorder 
with complete resolution of the illness occurring 
within six months. However, 15%-30% of the chil-
dren with ITP develop the chronic form of the dis-
ease defined as persistence of thrombocytopenia 
beyond six months. Children with chronic ITP 
(cITP) manifest variable clinical features and man-
agement is controversial [1-5]. Response rate to 
treatment is usually low in cITP; however, in some 
studies, high rates of spontaneous remission have 
been reported [6-8].
In addition to the acute and chronic forms of the 
disease, a recurrent course is also encountered in 
children. Recurrent ITP (rITP) is characterized by 
intermittent episodes of thrombocytopenia fol-
lowed by periods of recovery, unrelated to thera-
peutic intervention [9,10]. Although first described 
in 1961 [11], literature on this clinical course of the 
disease is limited. 
At present, the natural course of ITP is not fully 
understood. There are no established criteria 
regarding the clinical characteristics of the variant 
clinical courses, in order to predict the time and risk 
factors for a chronic outcome, response to treat-
ment and/or ultimate outcome. Furthermore, there 
is controversy regarding the classification of patients 
with recurrences.
The objective of our study was to evaluate the 
presenting features, diversity in clinical courses 
(including patients with recurrences), response to 
initial therapy, and long-term outcome in patients 
with ITP treated in our Pediatric Hematology Division 
and to share our single-institution, long-term, hospi-
tal-based experience together with related informa-
tion in the literature. 
Materials and Methods
Data Collection and Diagnosis
This retrospective, descriptive, cohort study was 
performed on patients with ITP diagnosed and fol-
lowed from January 1990 to December 2006 in the 
Pediatric Hematology Division, Tepecik Training and 
Research Hospital, İzmir, Turkey. Data regarding 491 
children with ITP were evaluated. There is ethical 
committee approval for the study. Patients less than 
6 months and over 16 years at initial diagnosis, non-
compliant patients and patients with proven sec-
ondary ITP were excluded. A total of 350 patients 
(186 females, 164 males) between the ages of 6 
months to 16 years were included in the study. 
Diagnosis of ITP was made by detailed physical 
examination and history, presence of thrombocyto-
penia (<150x109/L) with otherwise normal red cells 
and leukocytes, evaluation of Giemsa-stained 
peripheral blood smear and bone marrow aspira-
tion, and serological tests for infectious causes and 
autoimmune diseases [1]. 
Data collected from patients’ records included 
presenting hemorrhagic symptoms, age at diagno-
sis, gender, platelet count (PC) at diagnosis, the 
onset of each recurrence, number of recurrences, 
time elapsed between recurrences and from the 
initial diagnosis, treatment modality, response to 
treatment, follow-up duration, type of clinical 
course, preceding viral or bacterial infection, and 
medication or vaccination history. 
Definitions
Patients having low PC (<150x109/L) for less 
than 6 months were defined as acute ITP (aITP) and 
patients with thrombocytopenia persisting for more 
than 6 months after initial diagnosis were defined as 
cITP . Complete remission was defined as PC 
>150x109/L whereas partial remission was PC 
sayısı >20x109/L ve başvuru yaşının >10 yaş olmanın kronik ITP olasılığını 2 kat arttırdığı görüldü. 
Sonuç: Sonuç olarak ITP , çocukluk yaş grubunda mortalite ve morbiditesi düşük bir hastalıktır. Akut 
ve kronik seyirli ITP dışında, tüm ITP olgularının %4-7’sini oluşturan rekürren formların da olabileceği 
akılda tutulmalıdır. (Turk J Hematol 2010; 27: 147-55)
Anahtar kelimeler: İmmun trombositopenik purpura, çocuk, klinik seyir, kronik, rekürren, prognoz
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remission after initial diagnosis, but showing recur-
rences after at least 3 months of remission (with 
normal PCs) sustained without treatment and then 
relapsed were defined as rITP [10] (they achieved 
complete response to therapy after each recur-
rence and then relapsed). cITP patients were also 
evaluated in late-remission and non-remission sub-
groups. Chronic patients achieving normal PC after 
at least 6 months (usually 1-10 years) and maintain-
ing the normal PC values thereafter were defined as 
late-remission cITP . Patients who did not achieve 
normal PC values within the entire follow-up period 
were defined as non-remission cITP . 
Treatment
Patients with PC <20x109/L and/or bleeding 
symptoms at initial diagnosis were treated. Treatment 
consisted of high-dose methyl prednisolone (HDMP) 
or intravenous immunoglobulin (IVIG) and combi-
nation therapy of HDMP and IVIG, if the third-day 
PCs were still <20x109/L. In patients ≤2 years, the 
first choice of therapy was IVIG, whereas HDMP was 
the first choice in patients >2 years. IVIG was given 
at a dose of 1 g/kg/day for 2 days; HDMP was given 
at a dose of 30 mg/kg/day for 3 days and 20 mg/kg/
day for 4 days, consecutively and intravenously. For 
children >6 years, HDMP was given either orally or 
intravenously at the same dosage [5]. Regarding 
criteria for response to treatment, complete 
response (CR) was defined as PC >150x109/L and 
partial response (PR) as PC 50-149x109/L, including 
clinical recovery. PC <50x109/L was defined as non-
responsive (NR). 
Evaluation and Statistical Analysis
For statistical analysis, SPSS for Windows version 
13.0 was used. Independent samples t-test, Pearson 
χ2 test, Mann-Whitney U test and linear regression 
analysis were used. p<0.05 was accepted as statisti-
cally significant. 
Results
Among 350 patients with ITP , 186 were females; 
96.7% had presented with minor bleeding symp-
toms, either skin and/or mucosal hemorrhage. 
Three patients presented with epistaxis requiring 
nasal packing, 5 with gross hematuria and 5 with 
gastrointestinal bleeding in addition to minor bleed-
ing symptoms. 71% of the patients gave a history of 
viral illness 3-6 weeks prior to admission. 
Median age at diagnosis was 60 months 
(6 months-16 years) and median initial PC was 
9x109/L. Overall, patients were followed for a medi-
an 42 months (range: 7 months-16 years). Clinical 
forms were determined as aITP in 63.8%, cITP in 
29.1% and rITP in 7.1%.
Demographic, clinical and laboratory data of the 
aITP , cITP and rITP patients are shown in Table 1. 
Patients with aITP presented at a younger age 
(median 54 months) than both recurrent (median 
75 months) and chronic (median 78 months) 
patients (p<0.05, p<0.05). 22.5% of chronic patients, 
20% of recurrent patients and 11.7% of the aITP 
patients were >10 years of age. Initial PCs in aITP 
and rITP patients were significantly lower than in 
cITP (p<0.05, p<0.05). PC >20x109/L and initial 
diagnosis age >10 years were found to increase the 
probability of chronic outcome (odds ratio [OR]=2) 
by at least two-fold. Concerning the initial response 
rate to treatment, CR plus PR rates were highest in 
acute cases (87.4%), whereas 37.2% (n=38) of the 
chronic patients were found to be nonresponders. 
Three patients (12%) with rITP did not respond ini-
tially to HDMP but achieved CR by combination 
therapy (IVIG and HDMP) within 45-90 days. 
Comparison of the general characteristics of the 
aITP and cITP are shown in Table 2. Statistical differ-
ences were found in age at diagnosis, PC at diagno-
sis and response rate to initial treatment between 
acute and overall cITP (p<0.05). 
Age at diagnosis was not different in cITP vs rITP 
patients, whereas a significant difference was shown 
in aITP vs rITP patients (p>0.05). PC at diagnosis and 
response rate to initial treatment were not found sta-
tistically different between acute and recurrent 
patients (p>0.05). However, PC at diagnosis showed 
significant difference in cITP vs rITP (p<0.05). Initial 
response rate to treatment showed marginal signifi-
cance between cITP and rITP (p=0.05).
Regarding the 102 cITP patients, 77.5% were 
found to be in the non-remission group, whereas 
22.5% (n=23) achieved remission in a median 18 
months (8-66 months). Median age at diagnosis of 
the patients in non-remission and late-remission 
groups was 96 months and 42 months, respectively 
(p<0.05). 27.8% of the patients with non-remission 
cITP were >10 years of age, whereas 4.3% of the 
late remission group was >10 years at initial diagno-
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PC distribution within the follow-up period 
approached statistical significance between the two 
groups (p=0.000). Current status revealed no com-
plete remission and 27.8% partial remission in 
patients with non-remission cITP , whereas all of the 
patients in late-remission cITP achieved complete 
remission during the follow-up period (Table 3). 
Detailed data on the patients with rITP are pre-
sented in Table 4 and general characteristics and 
outcome of patients with rITP are given in Table 5. 
Median age at initial diagnosis of these patients was 
75 months (range: 22-146 months) with female pre-
dominance. PC at initial diagnosis was a median 
6x109/L. After achieving complete remission in a 
median 20 days (at initial diagnosis) and sustaining 
normal PC for a median 20 months, these patients 
experienced 1-4 recurrences within the follow-up 
period of 18-141 months. Fifteen patients (60%) had 
only one recurrence, whereas 7 (28%) patients had 
2, 2 (8%) patients had 3, and 1 (4%) patient had 4 
recurrences. The first recurrence was seen between 
8-109 months (median 20 months) after initial diag-
nosis. Time elapsed to 2nd, 3rd and 4th recurrence 
after diagnosis was 29, 67 and 58 months, respec-
tively (range: 12-117 months). Duration of each 
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Table 2. Comparison of the general characteristics of the patients with aITP and cITP 
   Acute Chronic  p
Gender, F / M   119/104  53/49  0.81
Age at diagnosis (months) *  54 (6-164)  78 (6-192)  0.00
PC at diagnosis (x109/L)*  8 (1-77)  14 (1-83)  0.00
 <20x109/L, n(%)  184 (82.5)  65 (63.7)  0.00
 >20x109/L, n(%)  39 (17.5)  37 (36.3)   
Response to initial treatment n(%) 
  Complete response  130 (58.2)  27 (26.5)  0.00
  Partial response  65 (29.2)  37 (36.3)
  No response  28 (12.6)  38 (37.2)
Follow-up duration (months) *   36 (7-132)  54 (8-174)  0.00
* Data are presented as median values (range)
Table 1. Demographic, clinical and laboratory data of the patients with aITP , cITP and rITP 
   Acute  Chronic  Recurrent
No. of patients   223  102  25
Gender, F/M   119/104  53/49  14/11
Age at initial diagnosis (months) *  54 (6-164)  78 (6-192)  75 (22-146)
 Age distribution at diagnosis, n (%)
  6-24 months   48 (21.5)  12 (11.8)  1 (4)
  25-60 months  76 (34.1)  30 (29.4)  9 (36)
  61-120 months  73 (32.7)  37 (36.3)  10 (40)
  >120 months  26 (11.7)  23 (22.5)  5 (20)
Platelet count at diagnosis (x109/L)*  8 (1-77)  14 (1-83)  6 (1-30)
Platelet count at 1 month (x109/L)* 21  (7-72)  30  (1-43)  131  (27-324)
Response to initial treatment, n (%)
  Complete response  130 (58.2)  27 (26.5)  12 (48)
  Partial response  65 (29.2)  37 (36.3)  9 (36)
  No response  28 (12.6)  38 (37.2)  3 (12)
Follow-up duration (months) *  36 (7-132)  54 (8-174)  72 (18-141)
* Data are presented as median values (range)recurrence was 5-11 days. Time interval between 
the recurrences was a median 12 months (range: 
4-50 months). Time elapsed after last remission was 
a median 24 months (6-99 months). Currently, these 
patients are all in complete remission. 
Out of 102 cITP patients, 30 (29.4%) underwent 
splenectomy. Median ages at diagnosis and at sple-
nectomy of these patients were 8.5 years and 10.7 
years, respectively. Patients were followed 12-170 
months after splenectomy, and within this period, 
73.3% achieved complete remission.
Of overall patients, 2 non-remission and 1 late-
remission patients with cITP revealed antinuclear 
antibody (ANA) positivity (1/400). Median age at 
diagnosis of these patients was 6.5 years and medi-
an follow-up duration was 5 years, during which 
neither clinical nor pathological laboratory data 
were detected. 
One male patient with non-remission cITP devel-
oped intracranial hemorrhage at the eighth month 
of diagnosis with a PC of 7x109/L; he did not respond 
to medical treatment and was splenectomized. 
None of the patients in the study group died. 
Discussion 
Immune thrombocytopenic purpura (ITP) is a 
common hemorrhagic disease with a heteroge-
neous background during childhood. It is likely that 
all pediatricians will encounter children with ITP at 
some time in their practice. There are still many 
questions to be answered regarding the natural 
progress of the clinical forms and the prediction of 
chronic or recurrent outcome, response to treat-
ment and ultimate outcome [1-10]. 
Our results concerning the acute and chronic 
patients were comparable with other series in 
terms of the incidence of clinical courses, mean/
median age at diagnosis, male/female ratio, initial 
PCs, and initial response rates to therapy [12-15]. At 
present, it is difficult to foresee at the time of diag-
nosis the patients who will develop a chronic 
course; although age older than 10 years, adoles-
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Table 4. Clinical and laboratory characteristics of thrombocytopenic 
episodes in rITP 
 Initial  1st 2 nd 3 rd 4 th
  Diagnosis 
No. of patients  25  25  10  3  1
PC x109/L*  6 (1-30)  9 (4-45) 11 (8-22)  4 (3-8)  37
Bleeding   25  20  7  1  0
manifestations** 
Treatment/no response
 IVIG or HDMP  24/3  22/4  8/0  2/0  0
 IVIG+HDMP  3/0  4/0  0  0  0
 No treatment  1/-  3/-  2/-  1/-  1/-
*Data are presented as median (range)
**Bleeding manifestations were all minor manifestations. 
IVIG: Intravenous immunoglobulin; HDMP: High-dose methylprednisolone
Table 3. Comparison of the 102 patients with cITP with different clinical courses 
   Non-remission Late-remission  p
No. of patients   79  23 
Gender, F /M  44/35  9/14  0.16
Age at diagnosis (months) *   96 (12-193)  42 (6-149)  0.00
Age distribution at diagnosis, n (%) 
  6-24 months  6 (7.6)  6 (26.1)
  25-120 months  51 (64.6)  16 (69.6)  0.00
  >120 months  22 (27.8)  1 (4.3)
PC at diagnosis (x109/L)*   14 (1-83)  13 (1-76)  0.81
Months to achieve remission *    18 (8-66)  -
Post-remission follow-up (months) *  -  42 (8-118)  -
Total follow-up (months) *  54 ( 8-180)  72 (18-156)  0.12
Current status n (%)
  Complete remission   0  23 (100)
  Partial remission  22 (27.8)  0  -
  No remission  57 (72.2)  0 
* Data are presented as median values (range)cence in females, and an initial PC >20x109/L have 
been associated with a chronic course [12-16]. In 
our study, initial PC >20x109/L and initial diagnosis 
age >10 years were found to increase the probabil-
ity of chronic outcome by at least two-fold (OR=2). 
Glanz et al. [16] reported an approximate five-fold 
risk for progressing to chronic disease in children 
whose illness was diagnosed at ≥10 years of age 
and who had PC ≥20x109/L. Kühne et al. [12] 
reported a high incidence of cITP (47.3%) in older 
children and adolescents. 
The majority of the children with cITP have mild 
bleeding episodes not requiring treatment despite 
persistent thrombocytopenia. In addition, rates of 
spontaneous recovery of 30-60% have been report-
ed many years after initial diagnosis [6-8]. In our 
cohort, 102 patients with cITP were evaluated in 
non-remission and late-remission subgroups. 
Twenty-three patients (22.5%) achieved complete 
remission in a median 18 months (8 months-66 
months). In 16 of the 23 patients, PC normalized at 
8-24 months. Currently, all of the patients in the late-
remission group achieved complete remission, 
whereas 27.8% and 72.2% of the patients in the non-
remission cITP subgroup revealed partial remission 
and no remission, respectively. Ruggiero et al. [6] 
reported 5 (41.6%) out of 12 cITP patients approach-
ing complete remission within 15-90 months. 
Donato et al. [8] reported a 32.9% rate of spontane-
ous remission in 325 nonsplenectomized children 
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Table 5. General characteristics and outcome of 25 patients with rITP 
No/sex  Age at Dx  PC at Dx  Days to achieve  Time of 1st  Time of 2nd  Time of 3rd Months  elapsed  Total
 Months  (x109/L)  initial CR**  recurrence   recurrence  recurrence  after last remission  follow-up*
        after Dx*  after Dx*  after Dx*  
1/F 124  13,000  30    38      41  79
2/M 86  2000 30  16      23  39
3/F 95  19,000  15  8  12    6  18
4/F 66  6000  20  71      6  77
5/M 45  20,000 5  12  22    68  90
6/F 98  7,000  10  9  20  70  6  76
7/F 41  13,000  30  60      36  96
8/M 51  5,000 60  30  37    99  136
9/F 62  5,000  15  109 117    24  141
10/M  22  8,000  20  13 19 67  53 120
11/F 125  4,000  30  25      68  93
12/F 52  30,000 10  61      80  141
13/M 120 4,000  10  36      96  132
14/M 48  20,000 30  34      19  53
15/M 151 5,000  40  26  48    12  60
16/F 45  6,000 90  9  34    19  53
17F 53  7,000 30  33      51  84
18/F 56  4,000 45  12  24    53  77
19/M  34  10,000  15  12 34 48  11  59
20/F 138  4,000  20  14      30  44
21/F 93  3,000  7  31      24  55
22/M 81 3,000  30  16      39  55
23/M 146  19,000  10  15      20  35
24/F 93  1,000 30  34      6  40
25/M 75 4,000  10  12      10  22
*months
Dx: Diagnosis; **CR: Complete responsewith cITP between 6 months to 11 years; 44.9% 
approached remission 6-12 months from diagnosis. 
In Jayabose et al.’s [7] series of 62 cITP patients, a 
56% spontaneous remission rate was reported. All of 
these authors recommended delay or omission of 
surgical treatment and reservation of splenectomy 
for patients with severe symptoms and non-respond-
ers. Imbach et al. [14] and Donato et al. [8] also 
reported that the cut-off value to define cITP should 
be changed from 6 months to 12 months. Our obser-
vation, too, showed that the cut-off point of cITP 
should be changed to 12 months since immune 
thrombocytopenia could persist beyond 6 months 
and could recover spontaneously in months to years. 
Recurrent ITP (rITP) is a rare clinical course of 
ITP . It was first described by Walker and Walker [11] 
in 1961, who defined it as recurrence of ITP after a 
prolonged remission. Later, Imbach [9] defined it as 
the recurrence of ITP after at least 3 months of 
remission (with normal PCs) sustained without any 
treatment, including splenectomy. Vranou et al. [19] 
defined rITP as isolated episodes of thrombocyto-
penic purpura following complete remission, non-
related to therapeutic intervention, regardless of the 
time interval elapsed between the episodes, and 
reported that the time interval between two epi-
sodes less than 1-3 months was identified in 31.1% 
of the recurrences. Therefore, there is no consen-
sus in the literature about the definition of rITP as to 
the interval between the episodes.
Since 1961, only series with small numbers of 
patients have been published on rITP [10,17-20]. 
Jayabose et al. [10] reported 14 (4.1%) children with 
rITP among 340 pediatric patients. Median time to 
recurrence of these patients was 33 months (4-120 
months). Twelve (86%) patients had favorable out-
come, with 71% achieving complete plus partial 
remission and 14.2% achieving complete remission 
after splenectomy. Vranou et al. [19] gave the inci-
dence of rITP as 6% in their childhood ITP series. The 
majority of their rITP patients had only one recur-
rence (1-4 recurrences). The time interval between 
the two recurrences was longer than 3 months (up to 
96 months) in two-thirds of the episodes. They 
observed that the initial episode and the first recur-
rence generally shared the features of aITP . 
The incidence of rITP in our series was 7.1% (25 
of 350 patients), which is the highest of those 
reported by Khalifa et al. [18], Jayabose et al. [10]
and Vranou et al. [19]. Within the follow-up period 
of 18-141 months, these patients experienced 1 to 4 
recurrences. Sixty percent (n=15) had only one, 
28% (n=7) had two, 8% (n=2) had three, and 4% 
(n=1) had four recurrences. Median time elapsed 
to first recurrence after diagnosis was 20 months 
(8-109 months). The time interval before any recur-
rence was longer than four months (up to 50 
months). It was also noted that these patients had 
low PC at initial diagnosis and at 1st, 2nd and 3rd 
recurrences and had achieved complete remission 
at 5-11 days during the recurrence. In addition, rITP 
and aITP were found comparable in terms of PC at 
initial diagnosis and response rate to initial treat-
ment, whereas rITP was found comparable to cITP 
regarding age at diagnosis. PCs at initial diagnosis 
and during the thrombocytopenic episodes in rITP 
patients were as low as seen in patients with aITP . 
We found that the bleeding manifestations in our 
rITP patients were more prominent in the initial 
presentation and in the first recurrence, in accor-
dance with the study by Vranou et al. [19], and the 
bleeding manifestations were less than expected 
for the low PC in the 2nd, 3rd and 4th recurrences.
There are contradictory reports on the classifica-
tion of the patients with recurrences. rITP is believed 
by some to be an exacerbation during the course of 
a compensated cITP , probably triggered by viral 
infection [21,22]. In some reviews, it is mentioned 
as a separate form [10,18,19]. However, Roganovic 
et al. [20] reported that it could be characterized as 
“recurrent acute ITP” or what has been called by 
Dameshek et al. [17] “intermittent acute ITP”. 
Dameshek et al. [17] showed that recurrent acute 
ITP was distinct from cITP since platelet survival 
between episodes was found normal. Our experi-
ence with rITP showed us that the majority of these 
patients generally shared the clinical and hemato-
logical features of aITP (low initial PC, high response 
rate to initial treatment, mild and self-limited course 
and excellent prognosis). None of these patients 
presented with major bleeding at any recurrence 
and none of the patients needed splenectomy. Even 
though most of these patients presented with low 
PCs at recurrences, responses to treatment were 
excellent. Preceding viral infection was noted in 16 
patients at initial diagnosis. No previous history of 
vaccination or medication of any kind was detected 
at any recurrence. Unlike our favorable results in 
patients with rITP , Vranou et al. [19] and Jayabose et 
al. [10] reported 2 cases with rITP who developed 
intracranial hemorrhage, 1 being fatal. Also, 2 of 14 
patients of Jayabose et al. [10] achieved complete 
remission after splenectomy. The discrepancy 
between the results of the study groups shows that 
Yaprak et al.
Clinical course in children with ITP Turk J Hematol 2010; 27: 147-55 153definition, pathogenesis and outcome of rITP 
requires more data to be reported. 
Splenectomy remains an effective therapeutic 
option for patients with cITP with severe symptoms 
and/or nonresponders to pharmacological treat-
ment [23]. The rate of splenectomy performed for 
children with cITP ranges between 9% and 39% in 
the literature [23-27]. However, there are no cur-
rently available reliable factors predictive of whom 
and when to splenectomize and/or foresee the 
response rate to splenectomy. In our population of 
102 cITP patients, 29.4% (n=30) underwent sple-
nectomy with a CR rate of 73.3% and a PR rate of 
6.7%. Median ages at initial diagnosis and at sple-
nectomy were 8.5 years and 10.7 years, respectively. 
Fourteen patients underwent splenectomy between 
8-16 months, 6 patients between 2-3 years and 8 
patients more than 3 years after the initial diagnosis.
None of the children with ITP had serious bleed-
ing manifestations within the total follow-up period 
except a three-year-old male patient who experi-
enced an intracranial hemorrhage at the seventh 
month of diagnosis with a PC=7x109/L, who had 
shown no response to pharmacological therapy; he 
was splenectomized. He is now six years old and is 
being followed in our hematology division without 
neurological sequelae and with PC at 30-50x109/L.
In conclusion, ITP in childhood is a hemorrhagic 
disease with diverse natural history. Its heteroge-
neous background and lack of long-term clinical 
data cause controversies in classifying and manag-
ing patients with ITP . Our experience shows that a 
late-remission course in patients with cITP should 
be considered and the cut-off value to define cITP 
should be changed to 12 months. Children with PC 
>20x109/L at initial diagnosis and age at diagnosis 
>10 years have a two-fold risk for progression to 
chronic disease. rITP , a rare clinical course that 
seems to be mild and self-limiting and generally 
shares the clinical and hematological features of 
aITP , should also be considered. Splenectomy should 
be delayed and reserved for children with severe 
symptoms and/or non-responders. Prospective inter-
national long-term studies are needed to enlighten 
the natural history of the clinical courses and the 
final outcome in children with ITP .
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